Drug Profile
Research programme: cancer immunotherapeutics - Daiichi Sankyo Company/Zymeworks
Latest Information Update: 18 Jan 2021
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; Zymeworks
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 18 Jan 2021 Preclinical trials in Cancer in USA, Canada (unspecified route) (Zymeworks pipeline, January 2021)
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in Canada
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in USA